AAP
PYXS icon

Arax Advisory Partners’s Pyxis Oncology PYXS Stock Holding History

Arax Advisory Partners’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20 Sell
1
-13
-93% -$20 ﹤0.01% 3718
2025
Q4 		$16 Hold
14
– – ﹤0.01% 4038
2025
Q3 		$31 Buy
+14
New +$20 ﹤0.01% 3557

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arax Advisory Partners's PYXS Position: Q1 2026 in Review

Arax Advisory Partners reduced its Pyxis Oncology (PYXS) stake by 93% in Q1 2026, selling an estimated $20 and leaving 1 share worth $20. The position accounts for ﹤0.01% of the portfolio, ranked #3718.

Arax Advisory Partners first reported a position in PYXS in Q3 2025 and has held it in 3 quarters since. The position peaked at $31 in Q3 2025. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • Arax Advisory Partners held 1 share of Pyxis Oncology worth $20 as of Q1 2026.
  • Arax Advisory Partners sold 13 Pyxis Oncology shares in Q1 2026, an estimated $20.
  • Pyxis Oncology made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3718 holding.
  • Arax Advisory Partners first reported a position in Pyxis Oncology in Q3 2025 and has held it in 3 quarters since.
  • Arax Advisory Partners's Pyxis Oncology position peaked at $31 in Q3 2025.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.